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WITHOUT MUSCULOSKELETAL SIDE EFFECTS
D. Piecha1, V. Baragi2, A. Jaworski1, B. Korniski2, D. Nix2,
T. Powers2, C. Steeneck1, A. Taveras2, J. VanVelduizen2,
J. Weik1, M. Hofmann1
1Alantos Pharmaceuticals, Heidelberg, Germany, 2Alantos
Pharmaceuticals, Cambridge, MA
Purpose: Broad-spectrum MMP inhibitors have shown efficacy
in a variety of animal models of osteoarthritis (OA) and in-
flammation. However the clinical utility of these inhibitors has
been restricted by musculoskeletal side effects (MSS). While the
mechanism of this toxicity remains unclear, it has been reported
that non-selective inhibition of multiple MMPs may be responsible
for the observed toxicities. MMP-13 being the most potent type II
collagenase, is highly up-regulated in OA/RA and is responsible
for the degradation of human cartilage. Therefore selective inhi-
bition of MMP-13 may provide the desired cartilage degradation
protection needed for potential treatment of OA while overcoming
the MSS toxicity seen by non-selective inhibition of MMPs.
Methods: Cartilage penetration and extraction. Rat model of
MSS.
Results: We have identified a new class of potent, highly selec-
tive, non-zinc-binding MMP-13 inhibitors with excellent efficacy
in an in vitro cartilage degradation assay (data shown in sec-
ond poster). In vitro penetration experiments showed that these
inhibitors penetrated and accumulated in the cartilage while in
vivo studies with ALS 1-0635 demonstrated excellent oral avail-
ability and effective penetration into rat cartilage. Furthermore,
rats treated with ALS 1-0635 (100 mg/kg/day, p.o.) did not exhibit
musculoskeletal side-effects in the 14-day rat model of MSS and
showed no signs of clinical or histological changes characteristic
of musculoskeletal toxicity. While the positive control compound,
marimastat, a broad-spectrum MMP inhibitor, caused significant
toxicity (6.25 mg/kg/day dosed i.p. via Alzet pump) characterized
by soft tissue and bone changes, increased epiphyseal growth
plate, synovial hyperplasia and increased cellularity in the joint
capsule.
Conclusions: Our highly selective MMP-13 inhibitors repre-
sent a new class of orally bioavailable, cartilage-penetrating
compounds for the potential treatment of osteoarthritis without
the musculoskeletal toxicities that have plagued early MMP in-
hibitors.
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LONG-LASTING ANALGESIC EFFECT OF
INTRA-ARTICULAR INJECTION OF CROSS-LINKED
HYALURONATE GEL (GEL-200) ON ARTHRITIC PAIN
K. Yoshioka, K. Miyamoto, R. Abe, Y. Yasuda, N. Oshima,
H. Maruyama
Central Research Laboratories, Seikagaku Corporation, Tokyo,
Japan
Purpose: The objective of this study was to examine the long-
lasting analgesic effect and local retention of intra-articularly
injected cross-linked hyaluronate hydrogel (Gel-200), which has
been developed as a novel therapeutic agent for the knee os-
teoarthritis (OA).
Methods: 1) Determining the effects of Gel-200 on the
bradykinin-induced arthritic pain.
Gel-200, physiological saline or SUPARTZ® was administered
into the knee joint cavity of the left hind leg of female rats at a
dose of 0.05 mL/joint. On weeks 1, 2 and 4 after administration,
bradykinin (an endogenous hyperalgesic substance) with PGE2
(a pain enhancer) solutions were injected into the same joint
to induce arthritic pain. SUPARTZ® was only evaluated at 1
week, since this treatment typically requires reinjection once
a week. Under blinded conditions, the walking of the animal
was observed for about 2 minutes after injection of bradykinin
solutions and severity of pain was scored on a 5-point scale.
2) Determining the residual ratio of Gel-200 in joint cavity and
synovium of the knee in rabbits.
Gel-200 and its non-cross-linked intermediate (h-HAD), which
had same cross-linked agent as Gel-200, were administered into
the knee joint cavity in male rabbits at a dose of 0.05 mL/kg/joint.
Animals were sacrificed on days 1, 3, 5, 7, 14 and 28 after
administration, and synovial fluid and synovium were collected.
The common cross-linked agent of Gel-200 was quantified by
high performance liquid chromatography (HPLC) to calculate the
residual ratios of Gel-200 and h-HAD.
Results: 1) Gel-200 significantly suppressed the bradykinin-
induced pain response compared with control group at the time
points 1, 2 and 4 weeks post administration. The analgesic effect
by Gel-200 was more remarkable than that by SUPARTZ® at 1
week.
2) Most of Gel-200 disappeared from the synovial fluid within 7
days, however, it remained in the synovium for up to 28 days after
administration. By comparing the residual ratios of Gel-200 and
h-HAD, significantly higher levels of Gel-200 were detected in the
synovial fluid on days 1, 3 and 5 after administration. However, in
the synovium, the ratios of Gel-200 remained significantly higher
on days 7, 14, and 28. The results with h-HAD were similar to
those reported previously using 14C-hyaluronan.
Conclusions: It was demonstrated that Gel-200 administered
into the joint cavity was more effective against the arthritic pain
than SUPARTZ® and provided a sustained analgesic effect lasted
for at least 4 weeks. Furthermore, compared to non-cross-linked
hyaluronan, the injected Gel-200 remained in synovial fluid and
synovium for a prolonged period of time. Consequently, since
Gel-200 remains in the joint cavity longer, and is incorporated
into the synovium slowly, it is speculated that Gel-200 exerts a
long-lasting analgesic effect.
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ANALGESIC EFFECT OF CROSS-LINKED
HYALURONATE HYDROGEL (GEL-200) ON THE
MONOSODIUM URATE-INDUCED ARTHRITIC JOINT PAIN
IN DOGS
K. Takahashi, K. Yoshioka, K. Miyamoto, H. Maruyama
Central Research Laboratories, Seikagaku Corporation, Tokyo,
Japan
Purpose: The deposit of micro-crystals of monosodium urate
(MSU) in synovial fluid promotes acute inflammatory joint pain
in humans. The experimental joint pain model induced by an
intra-articular injection of MSU crystals has been widely used
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